Development of Tumor Cell-Based Vaccine with IL-12 Gene Electrotransfer as Adjuvant
Tumor cell-based vaccines use tumor cells as a source of tumor-associated antigens. In our study, we aimed to develop and test a tumor vaccine composed of tumor cells killed by irradiation combined with in vivo interleukin-12 gene electrotransfer as an adjuvant. Vaccination was performed in the skin...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-03-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/8/1/111 |
| _version_ | 1811185886801428480 |
|---|---|
| author | Tinkara Remic Gregor Sersa Katja Ursic Maja Cemazar Urska Kamensek |
| author_facet | Tinkara Remic Gregor Sersa Katja Ursic Maja Cemazar Urska Kamensek |
| author_sort | Tinkara Remic |
| collection | DOAJ |
| description | Tumor cell-based vaccines use tumor cells as a source of tumor-associated antigens. In our study, we aimed to develop and test a tumor vaccine composed of tumor cells killed by irradiation combined with in vivo interleukin-12 gene electrotransfer as an adjuvant. Vaccination was performed in the skin of B16-F10 malignant melanoma or CT26 colorectal carcinoma tumor-bearing mice, distant from the tumor site and combined with concurrent tumor irradiation. Vaccination was also performed before tumor inoculation in both tumor models and tumor outgrowth was followed. The antitumor efficacy of vaccination in combination with tumor irradiation or preventative vaccination varied between the tumor models. A synergistic effect between vaccination and irradiation was observed in the B16-F10, but not in the CT26 tumor model. In contrast, up to 56% of mice were protected from tumor outgrowth in the CT26 tumor model and none were protected in the B16-F10 tumor model. The results suggest a greater contribution of the therapeutic vaccination to tumor irradiation in a less immunogenic B16-F10 tumor model, in contrast to preventative vaccination, which has shown greater efficacy in a more immunogenic CT26 tumor model. Upon further optimization of the vaccination and irradiation regimen, our vaccine could present an alternative tumor cell-based vaccine. |
| first_indexed | 2024-04-11T13:36:56Z |
| format | Article |
| id | doaj.art-d4cdf2be78f5455cb0251808e5d6e3ac |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-04-11T13:36:56Z |
| publishDate | 2020-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-d4cdf2be78f5455cb0251808e5d6e3ac2022-12-22T04:21:26ZengMDPI AGVaccines2076-393X2020-03-018111110.3390/vaccines8010111vaccines8010111Development of Tumor Cell-Based Vaccine with IL-12 Gene Electrotransfer as AdjuvantTinkara Remic0Gregor Sersa1Katja Ursic2Maja Cemazar3Urska Kamensek4Department of Experimental Oncology, Institute of Oncology Ljubljana, Zaloska cesta 2, SI-1000 Ljubljana, SloveniaDepartment of Experimental Oncology, Institute of Oncology Ljubljana, Zaloska cesta 2, SI-1000 Ljubljana, SloveniaDepartment of Experimental Oncology, Institute of Oncology Ljubljana, Zaloska cesta 2, SI-1000 Ljubljana, SloveniaDepartment of Experimental Oncology, Institute of Oncology Ljubljana, Zaloska cesta 2, SI-1000 Ljubljana, SloveniaDepartment of Experimental Oncology, Institute of Oncology Ljubljana, Zaloska cesta 2, SI-1000 Ljubljana, SloveniaTumor cell-based vaccines use tumor cells as a source of tumor-associated antigens. In our study, we aimed to develop and test a tumor vaccine composed of tumor cells killed by irradiation combined with in vivo interleukin-12 gene electrotransfer as an adjuvant. Vaccination was performed in the skin of B16-F10 malignant melanoma or CT26 colorectal carcinoma tumor-bearing mice, distant from the tumor site and combined with concurrent tumor irradiation. Vaccination was also performed before tumor inoculation in both tumor models and tumor outgrowth was followed. The antitumor efficacy of vaccination in combination with tumor irradiation or preventative vaccination varied between the tumor models. A synergistic effect between vaccination and irradiation was observed in the B16-F10, but not in the CT26 tumor model. In contrast, up to 56% of mice were protected from tumor outgrowth in the CT26 tumor model and none were protected in the B16-F10 tumor model. The results suggest a greater contribution of the therapeutic vaccination to tumor irradiation in a less immunogenic B16-F10 tumor model, in contrast to preventative vaccination, which has shown greater efficacy in a more immunogenic CT26 tumor model. Upon further optimization of the vaccination and irradiation regimen, our vaccine could present an alternative tumor cell-based vaccine.https://www.mdpi.com/2076-393X/8/1/111tumor cell-based vaccineil-12gene electrotransferradiotherapyb16-f10ct26 |
| spellingShingle | Tinkara Remic Gregor Sersa Katja Ursic Maja Cemazar Urska Kamensek Development of Tumor Cell-Based Vaccine with IL-12 Gene Electrotransfer as Adjuvant Vaccines tumor cell-based vaccine il-12 gene electrotransfer radiotherapy b16-f10 ct26 |
| title | Development of Tumor Cell-Based Vaccine with IL-12 Gene Electrotransfer as Adjuvant |
| title_full | Development of Tumor Cell-Based Vaccine with IL-12 Gene Electrotransfer as Adjuvant |
| title_fullStr | Development of Tumor Cell-Based Vaccine with IL-12 Gene Electrotransfer as Adjuvant |
| title_full_unstemmed | Development of Tumor Cell-Based Vaccine with IL-12 Gene Electrotransfer as Adjuvant |
| title_short | Development of Tumor Cell-Based Vaccine with IL-12 Gene Electrotransfer as Adjuvant |
| title_sort | development of tumor cell based vaccine with il 12 gene electrotransfer as adjuvant |
| topic | tumor cell-based vaccine il-12 gene electrotransfer radiotherapy b16-f10 ct26 |
| url | https://www.mdpi.com/2076-393X/8/1/111 |
| work_keys_str_mv | AT tinkararemic developmentoftumorcellbasedvaccinewithil12geneelectrotransferasadjuvant AT gregorsersa developmentoftumorcellbasedvaccinewithil12geneelectrotransferasadjuvant AT katjaursic developmentoftumorcellbasedvaccinewithil12geneelectrotransferasadjuvant AT majacemazar developmentoftumorcellbasedvaccinewithil12geneelectrotransferasadjuvant AT urskakamensek developmentoftumorcellbasedvaccinewithil12geneelectrotransferasadjuvant |